Rhythm Amends LG Chem Deal, Secures Up to $750 Million Financing
Rhythm Pharmaceuticals amended its licensing agreement with LG Chem for investigational oral therapy bivamelagon and secured access to up to $750 million in financing to support the program and its broader portfolio.
WASHINGTON (dpa-AFX) - Rhythm Pharmaceuticals, Inc. (RYTM) has amended its licensing agreement with LG Chem for bivamelagon, an investigational oral therapy for rare obesity disorders, while also securing access to up to $750 million in financing to support the program and its broader portfolio.Biv…